Lake Street analyst Jacob Stephan raised the firm’s price target on Paysign (PAYS) to $9 from $7 and keeps a Buy rating on the shares after having hosted CFO Jeff Baker for investor meetings earlier this week. The firm came away from the meetings “feeling confident” in Paysign’s pharma pipeline, scalable operating model, and new plasma applications, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAYS:
- Paysign management to meet with Lake Street
- DA Davidson research director holds a bison roundup conference call
- 3 Best Stocks to Buy Now, 6/16/2025, According to Top Analysts
- Paysign price target raised to $8 from $7 at DA Davidson
- PaySign’s Strong Growth Potential and Strategic Positioning in Healthcare: A Buy Rating by Gary Prestopino